Drug Trial Radar · NCT02545049
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,352
Actual
Start
Sep 17, 2015
Primary completion
Feb 2, 2021
Study completion Feb 2, 2021
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
Conditions
- Diabetic Kidney Disease
Interventions
Finerenone (BAY94-8862)Drug
10 mg or 20 mg Finerenone tablet to be given orally, once daily.
PlaceboDrug
Matching placebo to be taken orally, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.Time frame: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
Locations
975 sites in 48 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Fort Payne, Alabama
Site not named
Huntsville, Alabama
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Prescott, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Bakersfield, California
Site not named
Chula Vista, California
Site not named
Dublin, California
Site not named
El Centro, California
Site not named
Fresno, California
Site not named
Fresno, California
Site not named
La Mesa, California
Site not named
Loma Linda, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Northridge, California
Site not named
Port Hueneme, California
Site not named
Poway, California
Site not named
Rancho Cucamonga, California
Site not named
Rialto, California
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
Santa Rosa, California
Site not named
Torrance, California
Site not named
Vista, California
Site not named
New Haven, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Fort Lauderdale, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Hialeah, Florida
Site not named
Hialeah, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Showing 40 of 975 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.